Sobi To Appeal Against EMA Rejection For Emapalumab
The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.
The company says its drug has demonstrated a positive benefit-risk profile in primary HLH in a post-approval real-life setting in the US since Food and Drug Administration approval in 2018.